HBM Holdings Ltd. is an investment company, which engages in the discovery and development of differentiated antibody therapeutics in oncology and immunology disease areas. It operates through the following geographical segments: Europe, Mainland China, United States, and Others. The company was founded by Xiao Xiang Chen, Qi He, Schweizer Liang, Mai Jing Liao, Xiao Xi Liu, and Jing Song Wang on July 20, 2016 and is headquartered in Suzhou, China.